Eli Lilly raised its annual profit forecast and reported first-quarter results ahead of expectations, supported by steady demand for Zepbound and Mounjaro. The update is the company's first since launching its oral GLP-1 pill Foundayo, adding a new product catalyst to an already strong obesity and diabetes franchise. The combination of raised guidance and better-than-expected results should be supportive for the stock.
Eli Lilly raised its annual profit forecast and reported first-quarter results ahead of expectations, supported by steady demand for Zepbound and Mounjaro. The update is the company's first since launching its oral GLP-1 pill Foundayo, adding a new product catalyst to an already strong obesity and diabetes franchise. The combination of raised guidance and better-than-expected results should be supportive for the stock.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.68
